Park National Corp OH lowered its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 4.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 147,725 shares of the company's stock after selling 6,407 shares during the quarter. Park National Corp OH's holdings in AstraZeneca were worth $10,858,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after purchasing an additional 2,789 shares during the last quarter. Perigon Wealth Management LLC lifted its holdings in AstraZeneca by 3.0% during the 4th quarter. Perigon Wealth Management LLC now owns 19,597 shares of the company's stock worth $1,311,000 after buying an additional 567 shares during the last quarter. Orca Wealth Management LLC purchased a new stake in AstraZeneca during the 4th quarter worth about $4,532,000. R Squared Ltd purchased a new stake in AstraZeneca during the 4th quarter worth about $111,000. Finally, Hantz Financial Services Inc. lifted its stake in AstraZeneca by 2.7% during the fourth quarter. Hantz Financial Services Inc. now owns 45,726 shares of the company's stock worth $2,996,000 after purchasing an additional 1,212 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Stock Performance
AZN stock traded up $1.95 on Friday, hitting $72.82. The company's stock had a trading volume of 8,033,731 shares, compared to its average volume of 5,194,017. The firm has a 50 day moving average of $69.38 and a two-hundred day moving average of $69.67. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The stock has a market cap of $225.83 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.
AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. During the same period in the prior year, the company earned $2.06 earnings per share. The business's revenue was up 7.2% compared to the same quarter last year. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently weighed in on AZN shares. BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Finally, Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $88.00.
Read Our Latest Report on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
